X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Sinovac’s Covid-19 vaccine gets approval in Thailand for emergency use

Content Team by Content Team
25th February 2021
in News
FSD Pharma Gets Go Ahead for Phase IIa COVID-19 Trial

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Chinese company Sinovac Biotech has obtained approval for its Covid-19 vaccine from Thailand’s Food and Drug Administration (FDA) for local emergency use prior to the launch of a vaccination programme in the country.

The country will receive its first batch of 200,000 vaccine doses from Sinovac, Bloomberg reported.

Thailand ordered a total of two million doses of the vaccine. The country is expecting delivery of the second batch of 800,000 doses next month and the third batch of one million in April.

Thailand FDA Secretary-General Paisarn Dunkum signed the emergency use approval, which is valid for a year.

Xinhua quoted an anonymous government official as saying that Prime Minister Prayut Chan-o-cha will arrive at the airport to monitor the vaccine delivery.

Prayut said that he might be among the first people in Thailand to receive the Chinese vaccine.

The Disease Control Department noted that at-risk individuals, such as medical workers, close contacts with Covid-19 patients, individuals with chronic illnesses and those aged 60 years and above will receive the first doses of the vaccine.

Earlier, the country approved AstraZeneca’s Covid-19 vaccine for emergency use, ordering 61 million doses of the vaccine. Siam Bioscience will produce the vaccine locally through technology transfer.

In a separate development, the National Yang Ming Chiao Tung University (NYCU) researchers identified four novel drug candidates for treating Covid-19.

The research team used artificial intelligence and big data analysis to analyse more than 250 3D structures of main proteases of Covid-19 and targeted potential key proteins that the virus uses to enter human cells.

The four drugs identified, anti-HIV drug Nelfinavir, anti-inflammatory drug JMY206 and hepatitis C protease inhibitors Boceprevir and Telaprevir, showed robust inhibition of viral entry.

Previous Post

UCB and Microsoft expand drug development partnership

Next Post

UNICEF signs COVID-19 vaccine supply agreement with AstraZeneca

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
UNICEF signs COVID-19 vaccine supply agreement with AstraZeneca

UNICEF signs COVID-19 vaccine supply agreement with AstraZeneca

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In